Adalimumab-Aaty
2 NDCs across 1 manufacturer|1 Generic,1 Brand
Adalimumab-Aaty is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $31 million on Adalimumab-Aaty across 3,688 claims for 692 beneficiaries.
Adalimumab-Aaty is available as 2 NDCs from 1 manufacturer (1 generic, 1 brand), with NADAC prices from $490.04 to $912.21 per EA — a 86% difference between cheapest and most expensive. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
1G / 1B
Manufacturers
1
competing in market
Price Spread
$490.04 – $912.21
per EA
7d Activity
avg -0.3% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
CELLTRION USA, Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing ADALIMUMAB-AATY
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
YUFLYMA(CF) 40 MG/0.4 ML AUTOINJECTOR | $912.2140 per EA | -0.15% |
ADALIMUMAB-AATY(CF) 40 MG/0.4 ML AUTOINJECTOR | $490.0367 per EA | -0.43% |
Frequently Asked Questions
What is Adalimumab-Aaty used to treat?
Adalimumab-Aaty is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Adalimumab-Aaty?
In 2024, Medicare Part D spent $31 million on Adalimumab-Aaty across 3,688 claims for 692 beneficiaries.
How many Adalimumab-Aaty products are on the market?
The Adalimumab-Aaty drug market contains 2 NDCs from 1 manufacturer — 1 generic and 1 brand product.
What is the price range for Adalimumab-Aaty?
NADAC reference prices for Adalimumab-Aaty range from $490.0367 to $912.2140 per EA — a 86% difference between cheapest and most expensive.
Is generic Adalimumab-Aaty cheaper than brand?
The average generic NADAC for Adalimumab-Aaty is $490.0367 per EA, versus $912.2140 for brand-labeled products — generic is about 46% cheaper on average.
Which manufacturers make Adalimumab-Aaty?
1 manufacturer lists Adalimumab-Aaty in NADAC. Ranked by number of NDCs, the largest are CELLTRION USA, Inc. (2).
How has the price of Adalimumab-Aaty changed recently?
Over the past 7 days, 0 Adalimumab-Aaty NDCs rose and 2 fell, with a market-wide average change of -0.3%.